Granzyme B-Targeting Radiopharmaceutical for Immunotherapy Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nuclear medicine imaging techniques, such as those using 18F-FDG, lack specificity for monitoring the efficacy of tumor immunotherapy and Granzyme B expression, limiting their ability to accurately predict and evaluate treatment outcomes in tumor immunotherapy and other diseases.
Innovation Solution
A Granzyme B-targeting complex is developed by coupling a Granzyme B-targeting molecule with a bifunctional chelating agent, which is then labeled with radionuclides for use in PET or SPECT imaging, allowing for noninvasive and specific monitoring of Granzyme B expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If 18F-FDG is used for PET imaging, then noninvasive imaging is achieved, but tumor specificity and ability to monitor immunotherapy efficacy are poor
Solution Approach 1:
The patent changes the targeting parameter from glucose metabolism (18F-FDG) to Granzyme B protein expression. By using a Granzyme B-targeting molecule with specific affinity for Granzyme B, the imaging agent achieves tumor-specific detection of immunotherapy efficacy while maintaining noninvasive PET imaging capabilities.
Solution Approach 2:
The patent introduces a Granzyme B-targeting molecule as an intermediary between the radionuclide and the biological target. This targeting molecule specifically binds to Granzyme B on the cell surface, enabling selective detection of immunotherapy-responsive tumors while maintaining the noninvasive imaging advantage.
2Reliability
If current immunotherapy drugs are used, then tumor elimination is attempted, but effective rate is low and early efficacy prediction is difficult
Solution Approach 1:
The patent provides real-time feedback on immunotherapy efficacy through Granzyme B expression monitoring. By detecting Granzyme B levels in tumors during treatment, clinicians can assess early response to immunotherapy and adjust treatment strategies accordingly, transforming the lack of feedback into an actionable monitoring capability.
Solution Approach 2:
The patent replaces indirect glucose metabolism monitoring with direct protein expression detection. By targeting Granzyme B specifically, the system provides more accurate and direct information about immunotherapy efficacy, substituting the indirect 18F-FDG mechanism with a specific protein-targeting approach.
3Ease of manufacture
If Granzyme B-targeting molecule is coupled with bifunctional chelating agent, then radiopharmaceutical preparation is enabled, but complex structure is formed
Solution Approach 1:
The patent uses a bifunctional chelating agent that simultaneously serves two functions: (1) binding the radionuclide and (2) maintaining the Granzyme B-targeting molecule's binding capability. This multi-functional design simplifies the overall structure compared to separate components while enabling radiopharmaceutical preparation.
Solution Approach 2:
The patent merges the chelating function and targeting function into a single integrated complex structure. By coupling the Granzyme B-targeting molecule with the bifunctional chelating agent, the system combines multiple functions in one molecule, facilitating radiopharmaceutical preparation while managing structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Granzyme B-targeting radiopharmaceutical enables quantitative and noninvasive monitoring of Granzyme B expression, improving the prediction and evaluation of tumor immunotherapy efficacy and providing broad clinical applications in tumor and autoimmune disease management.
Implementation Method 1
coupling a Granzyme B-targeting molecule with a bifunctional chelating agent, which is then labeled with radionuclides
Implementation Method 2
labeled with radionuclides such as 68Ga, 18F and 99mTc for nuclear medicine PET or SPECT imaging
Data Source
AI summary
The present invention belongs to the field of nuclear medicine and relates to a Granzyme B-targeting complex, a radiopharmaceutical, a preparation method therefor and a use thereof. A structure of the Granzyme B-targeting complex is shown in formula (I), where R is any one of a bifunctional chelating group or a derivative thereof for radionuclide labeling. The Granzyme B-targeting complex provided by the present invention can be prepared into the Granzyme B-targeting radiopharmaceutical through radionuclide labeling. The Granzyme B-targeting radiopharmaceutical provided is simple to prepare and has better pharmacokinetic characteristics and in vivo metabolic stability than other Granzyme B-targeting drugs. The expression level of Granzyme B in vivo can be monitored noninvasively by nuclear medicine imaging.